PPT-The Role of Imaging in Diagnosing IPF

HandsOn Case Studies Learning Objectives IPF Overview Clinical Presentation a ATS Diagnostic Criteria Inconsistent With UIP Pattern on HRCT Differential Diagnosis Testing Case 1 Case 1 . Case Presentation: Familial IPF. 56-year-old Hispanic female with a family history of aortic aneurysm underwent a routine chest CT to assess her aorta. No respiratory symptoms. Medical history . h/o SVT. (ILD). Mike McFarlane (CT1). 12/5/12. SLIME. What we’ll cover. Definition. Different types of ILD. Pathophysiology. Presentation. Investigations. Management. Prognosis. Clinical Scenario. Summary. What we won’t.... Diagnosing Idiopathic Pulmonary Fibrosis. FACULTY. Title. Affiliation. Learning Objectives. Explain the considerations associated with . clinical evaluation, imaging, and . biopsy. , in terms of differentially diagnosing . PULMONARY FIBROSIS MANAGEMENT STRATEGIES I. NOVEMBER 13, 2015. Pharmacologic therapy. Disclosures. Research Grants. Roche (. InterMune. ). Scientific Advisory Board . Roche (. InterMune. ). Boehringer. Educational Activity Learning Objective. Upon completion of this course, the participants should be able to:. Explain the considerations associated with clinical evaluation, imaging, and surgical . biopsy . . Content. Importance. . of. . early. . diagnosis. . Initial . clues. . to. . suspect. IPF . Guidelines for Diagnosis. Diagnostic algorithm for IPF. . Exclusion of other known causes . Other tests and tools . 56-year-old Hispanic female with a family history of aortic aneurysm underwent a routine chest CT to assess her aorta. No respiratory symptoms. Medical history . h/o SVT. Type 2 diabetes mellitus. Hypertension. The . Next Steps in Individualizing Treatment. Learning Objectives. As a result of attending this activity, participants should be able to. :. Select . appropriate therapies that reflect current evidence and/ or widely accepted guidelines that are individualized to patients . 1InformationforRecapitulating idiopathic pulmonary fibrosis related alveolar epithelial dysfunction in an iPSC-derived air-liquid interface modelEva Schruf1 Victoria Schroeder1 Huy Q Le1 Tanja Schnber January 2021. Summary - orvepitant first in class/category, novel treatment for debilitating chronic cough associated with the terminal orphan condition idiopathic pulmonary fibrosis. The NeRRe management team recently sold KaNDy Therapeutics to Bayer in a deal valued >$1b. When using our slides, please retain the source attribution:. These slides may not be published, posted online, or used in commercial presentations without permission. . Please contact . pce@practicingclinicians.com. for Fibrosis & Oncology. Corporate Presentation – April 2021. Disclaimer. This document has been prepared by Nuformix plc (the "Company") and is being . made available for the sole purpose of providing the recipients with background information about the Company. It. Università degli Studi di Padova. Terapia della fibrosi polmonare idiopatica. IPF is . an unpredictable and ultimately fatal age-related interstitial lung disease of unknown cause with a median survival of approximately 3-5 years after diagnosis. Department. of . Diseases. of the . Thorax. , Ospedale GB . Morgagni. , Forlì (I). Department. of . Respiratory. . Diseases. & . Allergy. , . Aarhus. . University. Hospital, . Aarhus. (DK).